Big Picture Outlook
According to markets & Markets, the drug delivery technology market is expected to reach USD $1,669.4 Billion by 2020 from USD $1,179.2 Billion in 2016, growing at a CAGR of 7.2% during the forecast period. Geographically, Asia is projected to grow the most during this period. Regarding routes of administration, the market is predominantly segmented into oral, injectable, topical, nasal, ocular, pulmonary, implantable, and transmucosa. From 3-D printing, to non-oral delivery of biologics, to advances in nanotechnology, the future for drug delivery is ripe with innovation, but what is likely primed for market success?
With the increasing prevalence of chronic diseases, as well as demand for biologics (notably peptides), technological advancements, and new product launches, these are some of the main factors driving growth in the drug delivery technology market. Additionally, self-administration & home care and an increased demand for biosimilars and generic drugs offer significant growth opportunities for drug delivery manufacturers.
In a nutshell, there will be a significant growth in both commercial delivery technologies and whacky novel approaches flooding the market over the next few years.
Starting from Scratch Worth it?
Developing a new drug that receives market approval can cost $2.6 billion, according to the Tufts Center for the Study of Drug Development. Given the high costs involved in the drug development process, formulating products that improve delivery has clear cost implications for the industry as well the patient experience. Certain factors play a part – bioavailability, drug release profile and effectiveness. Is the product for self-administration, likely to be for emergency use? Is it for a child or someone with swallowing issues such as the elderly? Does it need to be a slow release formula or take the form of suppositories? Addressing patient requirements can make the difference between a drug being taken correctly and not being taken at all, which may have adverse effects on the health of the patient.
Biologics Thriving?
Biologics are expanding rapidly (BCC Research states that the global market value for biologics is expected to reach $252 billion this year) especially within the peptide and protein areas. Commercial scale-up manufacturing continues to pose a problem due to the complexities of the products however the delivery market opportunities are plentiful. There are some exciting developments within oral delivery of peptides and proteins, which some consider the holy grail of drug delivery.
Size Doesn’t Matter?
The development of nanomedicines (including utilization of nanocrystals, nanoparticles, liposomes) has increased with conditions such as cancer, cardiovascular disease and obesity benefitting from the development of this form of drug delivery. There are also significant advances within targeted and localized delivery, opening up a new wave of products potential for drug manufacturers, not to mention developing modified release products.
Want to Learn More?
Are you interested to learn more innovative controlled product development and delivery approaches?
Consider participating or attending the 2021 Controlled & modified Drug Release Summit later this year in San Diego and walk away with 2 years worth of new product development strategies in just 3 days! Now in it’s 7th successful year and on course to be the biggest yet, join over 160 leading drug delivery, formulation and development experts this month and hear 45+ expert sessions. Attend and learn over 2 YEARS worth of new product development strategies, formulation approaches, delivery technologies and regulatory updates while decreasing drug product time-to-market in just 2 days! Additionally, this must-attend event will showcase the latest regulatory guidance updates and the implications for the industry.
The Next Generation of Drug Delivery: Where are we headed?
- 1. The Next Generation of Drug Delivery: Where are we headed? is awarded to
- 2. What’s next? BIOTECH STILL ADVANCING Innovation in biopharmaceutical drug product development is today, often driven by small biotech. A healthy venture capital market is now enabling small biotech companies to take their new treatments and products all the way through to commercialization for niche indications. While larger companies typically have the experience in- house to navigate complex regulatory processes and the ability to scale manufacturing flexibly to meet market demand, small and virtual biotech companies tend to lack this expertise due to their size and focus. The healthcare industry urgently needs to produce innovative new therapies if it is to overcome its critical, long-term challenge, ie the revenue gap produced by the industry’s failure to develop sufficient, new, patent-protected medical therapies to offset the revenues lost as existing products lose their patent protection
- 3. Big Picture Outlook According to markets & Markets, the drug delivery technology market is expected to reach USD $1,669.4 billion by 2020, growing at a CAGR of 7.2% during the forecast period. Geographically, Asia is projected to grow the most during this period. Regarding routes of administration, the market is predominantly segmented into oral, injectable, topical, nasal, ocular, pulmonary, implantable, and transmucosa. From 3-D printing, to non- oral delivery of biologics, to advances in nanotechnology, the future for drug delivery is ripe with innovation, but what is likely primed for market success? With the increasing prevalence of chronic diseases, as well as demand for biologics (notably peptides), technological advancements, and new product launches, these are some of the main factors driving growth in the drug delivery technology market. Additionally, self- administration & home care and an increased demand for biosimilars and generic drugs offer significant growth opportunities for drug delivery manufacturers. In a nutshell, there will be a significant growth in both commercial delivery technologies and whacky novel approaches flooding the market over the next few years.
- 4. Starting from Scratch Worth it? Developing a new drug that receives market approval can cost $2.6 billion, according to the Tufts Center for the Study of Drug Development. Given the high costs involved in the drug development process, formulating products that improve delivery has clear cost implications for the industry as well the patient experience. Certain factors play a part – bioavailability, drug release profile and effectiveness. Is the product for self-administration, likely to be for emergency use? Is it for a child or someone with swallowing issues such as the elderly? Does it need to be a slow release formula or take the form of suppositories? Addressing patient requirements can make the difference between a drug being taken correctly and not being taken at all, which may have adverse effects on the health of the patient.. Biologics Thriving? Biologics are expanding rapidly (BCC Research states that the global market value for biologics is expected to reach $252 billion this year) especially within the peptide and protein areas. Commercial scale-up manufacturing continues to pose a problem due to the complexities of the products however the delivery market opportunities are plentiful. There are some exciting developments within oral delivery of peptides and proteins, which some consider the holy grail of drug delivery.
- 5. Size Doesn’t Matter? The development of nanomedicines (including utilization of nanocrystals, nanoparticles, liposomes) has increased with conditions such as cancer, cardiovascular disease and obesity benefitting from the development of this form of drug delivery. There are also significant advances within targeted and localized delivery, opening up a new wave of products potential for drug manufacturers, not to mention developing modified release products. And the Rest? Another trend we are seeing is the combination of technology and healthcare. Companies such as Google are partnering with pharmaceutical manufacturers to aid in the diagnosis and understanding of biomarkers and to enable patients to access data more conveniently. As the market moves forward, expect to see an increase in the use of mobile devices and apps to capture data that may help to increase the health of the population and capture trends for education, care, adherence to treatment regimens and convenient drug delivery. Additionally, there are many more delivery technologies driving innovation as we know it, but have yet to be commercially adopted. However, these remain promising opportunities for industry in 2020 and beyond.
Recent Comments